Premium
Serum interleukin‐2 concentrations in Guillain‐Barré syndrome and chronic idiopathic demyelinating polyradiculoneuropathy: Comparison with other neurological diseases of presumed immunopathogenesis
Author(s) -
Hartung HansPeter,
Reiners Karlheinz,
Schmidt Beate,
Stoll Guido,
Toyka Klaus V.
Publication year - 1991
Publication title -
annals of neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.764
H-Index - 296
eISSN - 1531-8249
pISSN - 0364-5134
DOI - 10.1002/ana.410300110
Subject(s) - polyradiculoneuropathy , medicine , guillain barre syndrome , multiple sclerosis , polymyositis , immunology , pathogenesis , clinically isolated syndrome , gastroenterology , pathology
Serum concentrations of the cytokine interleukin‐2 (IL‐2) were quantitated by enzyme‐linked immunosorbent assay in 42 patients with Guillain‐Barré syndrome, 15 patients with chronic idiopathic demyelinating polyradiculoneuropathy, 37 patients with other neuropathies, 54 patients with other noninflammatory, nondemyelinating neurological disorders, and 26 healthy control subjects. We found markedly increased serum levels of IL‐2 in patients with Guillain‐Barré syndrome and to a much lesser extent, in patients with chronic idiopathic demyelinating polyradiculoneuropathy. Increased serum concentrations of IL‐2 in patients with Guillain‐Barré syndrome returned to normal in parallel with recovery from the disease. These findings suggest ongoing T‐cell proliferation in patients with Guillain‐Barré syndrome and some patients with chronic idiopathic demyelinating polyradiculoneuropathy. IL‐2 levels were also raised in patients with active multiple sclerosis, myasthenia gravis, and herpes simplex encephalitis, and some patients with polymyositis, invoking T cells in the pathogenesis of these diseases.